Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X

Basit Öğe Kaydı
dc.authoridAltun, Armagan/0000-0002-3233-8263
dc.authorwosidAltun, Armagan/ABB-5844-2020
dc.contributor.authorÖzçelik, F
dc.contributor.authorAltun, A
dc.contributor.authorÖzbay, G
dc.date.accessioned2024-06-12T10:55:29Z
dc.date.available2024-06-12T10:55:29Z
dc.date.issued1999
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Syndrome X is defined as typical angina pectoris, positive treadmill exercise test, negative intravenous ergonovine test, and angiographically normal coronary arteries. Hypothesis: In the present study, we investigated the antiischemic and antianginal effects of nisoldipine and ramipril in patients with syndrome X. Methods: After 2 weeks of the first wash-out period, 18 patients (7 men, 11 women, age 46 +/- 10 years) were given nisoldipine (NIS) 5 mg twice daily for 4 weeks, and after 2 weeks of the second wash-out period, the same patients were given ramipril (RAM) 2.5 mg once daily for 4 weeks. A treadmill exercise test with modified Bruce protocol was performed at the end of each period. Results: The time to angina in exercise (607 +/- 115 s-650 +/- 117 s, p = 0.006, vs. 630 +/- 114 s-660 +/- 123 s, p = 0.02), total exercise time (612 +/- 110 s-656 +/- 114 s, p = 0.0008, vs. 630 +/- 114 s-660 +/- 123 s, p = 0.02), and maximum MET value (11.09 +/- 2.08-11.86 2.04, p = 0.0016, vs. 11.42 +/- 2.09-12.2 +/- 2.26, p = 0.01) were increased significantly with both therapy modalities. The time to 1 mm ST-segment depression(123 +/- 93 s - 220 +/- 172 s, p = 0.002) was increased significantly with NIS therapy. The time to ST-segment recovery (434 +/- 268 s-330 +/- 233 s, p = 0.016 vs. 443 +/- 259 s-370 +/- 278 s, p = 0.012), the frequency of anginal attacks per week (1.27 +/- 1.4-0 +/- 0.38, p = 0.005, vs. 1 +/- 1.32-0.33 +/- 0.59, p = 0.028), and the need for sublingual nitroglycerin (1.16 +/- 1.29-0.11 +/- 0.32, p = 0.005, vs. 0.94 +/- 1.16-0.27 +/- 0.57, p = 0.012) were decreased significantly with both drugs. Conclusion: We observed that 10 mg daily NIS and 2.5 mg daily RAM have similar anti-ischemic and antianginal effects in patients with syndrome X.en_US
dc.identifier.endpage365en_US
dc.identifier.issn0160-9289
dc.identifier.issue5en_US
dc.identifier.pmid10326170en_US
dc.identifier.scopus2-s2.0-0345280782en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage361en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19447
dc.identifier.volume22en_US
dc.identifier.wosWOS:000080044600012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinical Cardiology Publ Coen_US
dc.relation.ispartofClinical Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCalcium-Channel Blockeren_US
dc.subjectAngiotensin-Converting Enzyme Inhibitoren_US
dc.subjectSyndrome Xen_US
dc.subjectAbnormal Vasodilator Reserveen_US
dc.subjectNormal Coronary-Arteriesen_US
dc.subjectAngina-Pectorisen_US
dc.subjectMicrovascular Anginaen_US
dc.subjectChest Painen_US
dc.subjectTherapyen_US
dc.subjectDiseaseen_US
dc.titleAntianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome Xen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu